

SEQUENCE LISTING

<110> ACADIA PHARMACEUTICALS INC.

<120> Use of the Lipoxin Receptor, FPRL1, as a Tool for Identifying
Compounds Effective in the Treatment of Pain and Inflammation

<130> 65167.00023

<140> 10590001

<141> 2007-05-25

<150> 10/590,001

<151> 2006-08-17

<150> PCT/US2004/036952

<151> 2004-11-04

<160> 2

<170> PatentIn version 3.3

<210> 1

<211> 2631

<212> DNA

<213> human neutrophils and monocytes *Homo/sapiens*

<400> 1

ggcacgagga acaacctatt tgcaaagttg gcgcaaacat tcctgcctga caggaccatg	60
gacacaggtt gtagagatag agatggctct ggctgtgcat tcagcagatt ctgtagatag	120
aattaattag gacttgatg ggatttgtgt gagagaaagt gaaatgaaag ataagttcta	180
gtttggaagt ttaacaact gaattgttaa actcaaatag acacaaaata ttggaagagt	240
ggcaggtttg ggaggatgag acaatcaact gtttggttga gccacgtag gtttgaaatg	300
tctacgggat cccgtgggga gaggttatat cagactggag caccagagag aggccaaggc	360
tgatagttta gatgaaaaga gagcatgata ttttaagccc tgagactgga taatatcacc	420
tatagaaaga ctatatagag ataagagagg tggggaacaa gtaaaagctg cgggacactc	480
ctaaatttag agtcaaattt agagcagaaa atactagcaa aggggactga aaagcgggtg	540
ccaattgagc ttcaaatgca agtgaaagtg tgttgtgtgt acatttatca tctcatggca	600
caggaaaaac gtgatttaag gagaaggaag cgatccaatg ggaagaagag atccaatgga	660
tcctctatca cgaagatatt gagataagaa ccaatatgga tttgcacca ctgcatttgc	720
agccttgagg tcataagcat cctcaggaaa atgcaccagg tgctgctggc aagatggaaa	780
ccaacttctc cactcctctg aatgaatatg aagaagtgtc cttgagtctg ctggctacac	840
tgttctgcgg atcctcccat tgggtgtgct tggggtcacc tttgtcctcg gggctctggg	900

caatgggctt gtgatctggg tggctggatt ccgatgaca cgcacagtca ccaccatctg	960
ttacctgaac ctggccctgg ctgacttttc ttacacggcc acattaccat tcctcattgt	1020
ctccatggcc atgggagaaa aatggccttt tggctgggtc ctgtgtaagt taattcacat	1080
cgtggtggac atcaacctct ttggaagtgt cttcttgatt ggtttcattg cactggaccg	1140
ctgcatttgt gtectgcac cagtctgggc ccagaaccac cgcactgtga gtctggccat	1200
gaaggtgac gtccgacctt ggattcttgc tctagtcctt accttgccag ttttctctt	1260
tttgactaca gtaactatta caaatgggga cacatcatgt actttcaact ttgcatcctg	1320
gggtggcacc cctgaggaga ggctgaaggt ggcattacc atgctgacag ccagagggat	1380
tatccgggtt gtcattggct ttagcttgcc gatgtccatt gttgccatct gctatgggct	1440
cattgcagcc aagatccaca aaaagggcat gattaaatcc agccgtccct tacgggtcct	1500
cactgctgtg gtggcttctt tcttcactg ttggtttccc tttcaactgg ttgcccttct	1560
gggcaccgtc tggtcaaag agatgttgtt ctatggcaag tacaaaatca ttgacatcct	1620
ggttaaccca acgagctccc tggccttctt caacagctgc ctcaacccca tgctttacgt	1680
ctttgtgggc caagacttcc gagagagact gatccactcc ctgcccacca gtctggagag	1740
ggccctgtct gaggactcag ccccaactaa tgacacggct gccaatctg cttcacctcc	1800
tgcagagact gagttacagg caatgtgagg atggggtcag ggatattttg agttctgttc	1860
atcctaccct aatgccagtt ccagcttcat ctacccttga gtcatttga ggcattcaag	1920
gatgcacagc tcaagtattt attcaggaaa aatgcttttg tgccttgat ttggggctaa	1980
gaaatagaca gtcaggctac taaaatatta gtgttatttt ttgttttttg acttctgcct	2040
ataccctggg gtaagtggag ttgggaaata caagaagaga aagaccagtg gggatttgta	2100
agacttagat gagatagcgc ataataaggg gaagacttta aagtataaag taaaatgttt	2160
gctgtaggtt ttttatagct attaaaaaaa atcagattat ggaagtttct ttctattttt	2220
agtttgctaa gagttttctg tttcttttct ttacatcatg atgtgacttt gcattttatc	2280
aaatgcattt tctacatgta ttaagatggc catattatct ttcttctttt atgtaaatca	2340
ttataaataa tgttcattaa gttctgaatg ttaaactact cttgaattcc tggaataaac	2400
cacacttagt cctgatgtac tttaaatatt tatatctcac aggagtgggt tagaatttct	2460
gtgtttatgt ttatatactg ttatttcaact ttttctacta tccttgctaa gttttcatag	2520
aaaataagga acaaagagaa acttgtaatg gtctctgaaa aggaattgag aagtaattcc	2580

tctgattctg ttttctgggt ttatatcttt attaaatatt cagaaaaatt c

2631

<210> 2

<211> 351

<212> PRT

<213> human neutrophils and monocytes

<400> 2

Met Glu Thr Asn Phe Ser Thr Pro Leu Asn Glu Tyr Glu Glu Val Ser
1 5 10 15

Tyr Glu Ser Ala Gly Tyr Thr Val Leu Arg Ile Leu Pro Leu Val Val
20 25 30

Leu Gly Val Thr Phe Val Leu Gly Gly Val Leu Gly Asn Gly Leu Val
35 40 45

Ile Trp Val Ala Gly Phe Arg Met Thr Arg Thr Val Thr Thr Ile Cys
50 55 60

Tyr Leu Asn Leu Ala Leu Ala Asp Phe Ser Phe Thr Ala Thr Leu Pro
65 70 75 80

Phe Leu Ile Val Ser Met Ala Met Gly Glu Lys Trp Pro Phe Gly Trp
85 90 95

Phe Leu Cys Lys Leu Ile His Ile Val Val Asp Ile Asn Leu Phe Gly
100 105 110

Ser Val Phe Leu Ile Gly Phe Ala Leu Asp Arg Cys Ile Cys Val Leu
115 120 125

His Pro Val Trp Ala Gln Asn His Arg Thr Val Ser Leu Ala Met Lys
130 135 140

Val Ile Val Gly Pro Trp Ile Leu Ala Leu Val Leu Thr Leu Pro Val
145 150 155 160

Phe Leu Phe Leu Thr Thr Val Thr Ile Pro Asn Gly Asp Thr Tyr Cys
165 170 175

Thr Phe Asn Phe Ala Ser Trp Gly Gly Thr Pro Glu Glu Arg Leu Lys
180 185 190

Val Ala Ile Thr Met Leu Thr Ala Arg Gly Ile Ile Arg Phe Val Ile
195 200 205

Gly Phe Ser Leu Pro Met Ser Ile Val Ala Ile Cys Tyr Gly Leu Ile
210 215 220

Ala Ala Lys Ile His Lys Lys Gly Met Ile Lys Ser Ser Arg Pro Leu
225 230 235 240

Arg Val Leu Thr Ala Val Val Ala Ser Phe Phe Ile Cys Trp Phe Pro
245 250 255

Phe Gln Leu Val Ala Leu Leu Gly Thr Val Trp Leu Lys Glu Met Leu
260 265 270

Phe Tyr Gly Lys Tyr Lys Ile Ile Asp Ile Leu Val Asn Pro Thr Ser
275 280 285

Ser Leu Ala Phe Phe Asn Ser Cys Leu Asn Pro Met Leu Tyr Val Phe
290 295 300

Val Gly Gln Asp Phe Arg Glu Arg Leu Ile His Ser Leu Pro Thr Ser
305 310 315 320

Leu Glu Arg Ala Leu Ser Glu Asp Ser Ala Pro Thr Asn Asp Thr Ala
325 330 335

Ala Asn Ser Ala Ser Pro Pro Ala Glu Thr Glu Leu Gln Ala Met
340 345 350

33998-705.831 seq listing_ST25.txt
SEQUENCE LISTING

<110> Nash, Norman
Scully, Audra
Gardell, Luis
Olsson, Roger
Gustafsson, Magnus

<120> USE OF LIPOXIN RECEPTOR, FPRL1, AS A TOOL FOR IDENTIFYING
COMPOUNDS EFFECTIVE IN THE TREATMENT OF PAIN AND INFLAMMATION

<130> 33998-705.831

<140> US 10/590,001

<141> 2006-08-17

<150> PCT/US2004/036952

<151> 2004-11-04

<160> 2

<170> PatentIn version 3.4

<210> 1

<211> 2631

<212> DNA

<213> Homo sapiens

<400> 1

ggcacgagga acaacctatt tgcaaagttg gcgcaaacat tcctgcctga caggaccatg	60
gacacagggt gtagagatag agatggctct ggctgtgcat tcagcagatt ctgtagatag	120
aattaatagg acttggatgg gatttgtggtg agagaaagtg aaatgaaaga taagttctag	180
tttggaagtt ttaacaactg aatgttttaa ctcaaataga cacaaaatat tggaagagtg	240
gcaggtttgg gaggatgaga caatcaactg tttggttgag ccacgttagg tttgaaatgt	300
ctacgggatc ccgtggggag aggttatatc agactggagc accagagaga ggccaaggct	360
gatagtttag atgaaaagag agcatgatat ttttaagcct gagactggat aatatcacct	420
atagaaagac tatatagaga taagagaggt ggggaacaag taaaagctgc gggacactcc	480
taaatttaga gtcaaattta gaggagaaaa tactagcaaa ggggactgaa aagcgggtggc	540
caattgagct tcaaatgcaa gtgaaagtgt gttgtgtgta catttatcat ctcatggcac	600
aggaaaaacg tgatttaagg agaaggaagc gatccaatgg gaagaagaga tccaatggat	660
cctctatcac gaagatattg agataagaac caatatggat ttgcaccac tgcatattgca	720
gccttgaggt cataagcatc ctgaggaaaa tgcaccaggt gctgctggca agatggaaac	780
caacttctcc actcctctga atgaatatga agaagtgtcc tatgagtctg ctggctacac	840
tgttctgcgg atcctcccat tgggtggtgct tggggtcacc tttgtcctcg gggtcctggg	900
caatgggctt gtgatctggg tggctggatt ccgatgaca cgcacagtca ccaccatctg	960
ttacctgaac ctggccctgg ctgacttttc tttcacggcc acattaccat tcctcattgt	1020

33998-705.831 seq listing_ST25.txt

ctccatggcc atgggagaaa aatggccttt tggctggttc ctgtgtaagt taattcacat	1080
cgtggtggac atcaacctct ttggaagtgt cttcttgatt ggtttcattg cactggaccg	1140
ctgcatttgt gtcctgcatc cagtctgggc ccagaaccac cgcactgtga gtctggccat	1200
gaaggtgata gtcggacctt ggattcttgc tctagtcctt accttgccag ttttcctctt	1260
tttgactaca gtaactatta caaatgggga cacatcatgt actttcaact ttgcatcctg	1320
gggtggcacc cctgaggaga ggctgaaggt ggccattacc atgctgacag ccagagggat	1380
tatccggttt gtcattggct ttagcttgcc gatgtccatt gttgccatct gctatgggct	1440
cattgcagcc aagatccaca aaaagggcat gattaaatcc agccgtccct tacgggtcct	1500
cactgctgtg gtggcttctt tcttcactctg ttggtttccc tttcaactgg ttgcccttct	1560
gggcaccgtc tggctcaaag agatgttggt ctatggcaag taaaaatca ttgacatcct	1620
ggttaacca acgagctccc tggccttctt caacagctgc ctcaaccca tgctttacgt	1680
ctttgtgggc caagacttcc gagagagact gatccactcc ctgcccacca gtctggagag	1740
ggccctgtct gaggactcag cccaactaa tgacacggct gccaatctctg cttcacctcc	1800
tgagagact gagttacagg caatgtgagg atggggcag ggatattttg agttctgttc	1860
atcctaccct aatgccagtt ccagcttcat ctacccttga gtcattttga ggcattcaag	1920
gatgcacagc tcaagtattt attcaggaaa aatgcttttg tgtccctgat ttggggctaa	1980
gaaatagaca gtcaggctac taaaatatta gtgttatttt ttgttttttg acttctgcct	2040
ataccctggg gtaagtggag ttgggaaata caagaagaga aagaccagtg gggatttgta	2100
agacttagat gagatagcgc ataataaggg gaagacttta aagtataaag taaaatgttt	2160
gctgtaggtt ttttatagct attaaaaaaa atcagattat ggaagttttc ttctattttt	2220
agtttgctaa gagttttctg tttctttttc ttacatcatg atgtgacttt gcattttatc	2280
aaatgcattt tctacatgta ttaagatggg catattattc ttcttctttt atgtaaatca	2340
ttataaataa tgttcattaa gttctgaatg ttaaactact cttgaattcc tggaataaac	2400
cacacttagt cctgatgtac tttaaatatt tatatctcac aggagtgggt tagaatttct	2460
gtgtttatgt ttatatactg ttatttcact ttttctacta tccttgctaa gttttcatag	2520
aaaataagga acaaagagaa acttgtaatg gtctctgaaa aggaattgag aagtaattcc	2580
tctgattctg ttttctggtg ttatatcttt attaaatatt cagaaaaatt c	2631

<210> 2
 <211> 351
 <212> PRT
 <213> Homo sapiens

<400> 2

Met Glu Thr Asn Phe Ser Thr Pro Leu Asn Glu Tyr Glu Glu Val Ser

```

1           5           10           15
Tyr Glu Ser Ala Gly Tyr Thr Val Leu Arg Ile Leu Pro Leu Val Val
20           25           30
Leu Gly Val Thr Phe Val Leu Gly Val Leu Gly Asn Gly Leu Val Ile
35           40           45
Trp Val Ala Gly Phe Arg Met Thr Arg Thr Val Thr Thr Ile Cys Tyr
50           55           60
Leu Asn Leu Ala Leu Ala Asp Phe Ser Phe Thr Ala Thr Leu Pro Phe
65           70           75           80
Leu Ile Val Ser Met Ala Met Gly Glu Lys Trp Pro Phe Gly Trp Phe
85           90           95
Leu Cys Lys Leu Ile His Ile Val Val Asp Ile Asn Leu Phe Gly Ser
100          105          110
Val Phe Leu Ile Gly Phe Ile Ala Leu Asp Arg Cys Ile Cys Val Leu
115          120          125
His Pro Val Trp Ala Gln Asn His Arg Thr Val Ser Leu Ala Met Lys
130          135          140
Val Ile Val Gly Pro Trp Ile Leu Ala Leu Val Leu Thr Leu Pro Val
145          150          155          160
Phe Leu Phe Leu Thr Thr Val Thr Ile Pro Asn Gly Asp Thr Tyr Cys
165          170          175
Thr Phe Asn Phe Ala Ser Trp Gly Gly Thr Pro Glu Glu Arg Leu Lys
180          185          190
Val Ala Ile Thr Met Leu Thr Ala Arg Gly Ile Ile Arg Phe Val Ile
195          200          205
Gly Phe Ser Leu Pro Met Ser Ile Val Ala Ile Cys Tyr Gly Leu Ile
210          215          220
Ala Ala Lys Ile His Lys Lys Gly Met Ile Lys Ser Ser Arg Pro Leu
225          230          235          240
Arg Val Leu Thr Ala Val Val Ala Ser Phe Phe Ile Cys Trp Phe Pro
245          250          255

```

33998-705.831.seq listing_ST25.txt

Phe Gln Leu Val Ala Leu Leu Gly Thr Val Trp Leu Lys Glu Met Leu
260 265 270

Phe Tyr Gly Lys Tyr Lys Ile Ile Asp Ile Leu Val Asn Pro Thr Ser
275 280 285

Ser Leu Ala Phe Phe Asn Ser Cys Leu Asn Pro Met Leu Tyr Val Phe
290 295 300

Val Gly Gln Asp Phe Arg Glu Arg Leu Ile His Ser Leu Pro Thr Ser
305 310 315 320

Leu Glu Arg Ala Leu Ser Glu Asp Ser Ala Pro Thr Asn Asp Thr Ala
325 330 335

Ala Asn Ser Ala Ser Pro Pro Ala Glu Thr Glu Leu Gln Ala Met
340 345 350